Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Associations of genetic variants in ABCB1, ABCG2, CYP3A4, CYP3A5, and SLCO1B1 with statin-associated muscle symptom (SAMS) in South African populations
Background: Dyslipidaemia, particularly elevated plasma LDL-cholesterol levels, is a key modifiable risk factor for cardiovascular disease (CVD). Statins recognized as LDL-c lowering drugs, have traditionally been the cornerstone in dyslipidaemia treatment and are reported to reduce CVD mortality by...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Language: | Eng |
| Published: |
Department of Pathology
2025
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867613597401612288 |
|---|---|
| access_status_str | Open Access |
| author | Lusiki, Zizo |
| author2 | Dandara, Collet |
| author_browse | Dandara, Collet Lusiki, Zizo |
| author_facet | Dandara, Collet Lusiki, Zizo |
| author_sort | Lusiki, Zizo |
| collection | Thesis |
| description | Background: Dyslipidaemia, particularly elevated plasma LDL-cholesterol levels, is a key modifiable risk factor for cardiovascular disease (CVD). Statins recognized as LDL-c lowering drugs, have traditionally been the cornerstone in dyslipidaemia treatment and are reported to reduce CVD mortality by 20-30%. However, over the years, the efficacy of statins has been compromised by the emergence of adverse effects, especially statinassociated muscle symptoms (SAMS). Strong evidence links SAMS susceptibility to pharmacogenetic variability of ABCB1, ABCG2, CYP3A4, CYP3A5, and SLCO1B1, particularly in Asian and European populations. However, limited knowledge exists regarding the impact of pharmacogenetics on statin tolerance among South African patients. This study aimed to examine the relationships between genetic variants in the five pharmacogenes mentioned and SAMS in a cohort of dyslipidaemia patients from South Africa undergoing statin treatment. Methods: Employing a retrospective matched case-control (1:2) study design, we assessed a cohort of 332 dyslipidaemia patients from Groote Schuur Hospital, South Africa. Most patients were of Mixed Ancestry. A lipid expert determined SAMS status through adjudication. Genetic variants in five key genes—ABCB1 (rs1045642), ABCG2 (rs2231142, rs2199939), CYP3A4 (rs2740574), CYP3A5 (rs776746, rs10264272, and rs41303343), and SLCO1B1 (rs4149056, rs2306283, and rs4363657)—were chosen for genotyping, using PCR-RFLP, TaqMan genotyping assays, and validated through Sanger sequencing. Statistical analysis, encompassing Chi-Square, Mann-Whitney U (Wilcoxon rank sum), and logistic regression tests, was conducted using STATA v15 and R, while linkage disequilibrium and haplotype analysis were performed using SHEsis online software. Non-genetic and genetic variables were correlated with SAMS status. Results: The median age of patients was 58 years, with 50% being female. Univariate analysis revealed significant associations of SAMS with BMI (p=0.026), waist circumference (p=0.03), and triglyceride levels (p=0.01). The ABCB1 rs1045642 C/T genotype (56.36%, OR=1.86, 95%CI=1.10-3.14, p=0.02) was more prevalent among patients with SAMS compared to those without. Conversely, ABCG2 rs2231142 A/A (6.31%, OR=0.13, 95%CI=0-0.81, p=0.02) and SLCO1B1 rs4149056 C/C (6.76%, OR=0.14, 95%CI=0-0.84, p= 0.03) genotypes were significantly less prevalent in cases than controls. The ABCG2 rs2231142A variant allele occurred more frequently in controls (p=0.03). Multivariate analysis, incorporating genetic and clinical variables through stepwise logistic regression, identified ABCB1 rs1045642 C/T as the sole significant predictor for SAMS in this cohort. Moreover, the SLCO1B1 rs4149056T>C and SLCO1B1 rs4363657T>C polymorphisms exhibited strong linkage disequilibrium—further analysis identified six inferred haplotypes for SLCO1B1. Haplotype 6 (G-T-T) was significantly more prevalent in cases (38.9%, OR=1.44, 95%CI=1.03-2.03, p=0.03) than in controls. Conversely, haplotype 2 (G-C-C) exhibited a significantly higher occurrence in controls (6.8%, OR=0.23, 95%CI=0.08-0.69, p=0.04) than in cases. Conclusion: This study underscores the role of genetic variations in ABCB1, ABCG2, and SLCO1B1 in predisposing South African Mixed Ancestry patients to SAMS. Specifically, ABCB1 rs1045642 C/T genotype emerged as a significant predictor for SAMS in this cohort, indicating its potential role in statin toxicity. Significant differences were observed in the distribution of variant alleles for most SNPs in our cohort compared to global populations, suggesting that universal guidelines may not be universally applicable. This observation was further supported by disparities in inferred haplotypes, underscoring the necessity for comprehensive pharmacogenetic studies within the South African population. These findings expand our knowledge of SAMS in a population with limited pharmacogenomic data, potentially informing personalized statin therapy. Key Words: dyslipidaemia, SAMS, pharmacogenetics, ABCB1, ABCG2, SLCO1B1, South African |
| format | Thesis |
| id | oai:open.uct.ac.za:11427/41087 |
| institution | University of Cape Town (South Africa) |
| language | Eng |
| last_indexed | 2026-06-10T12:38:40.813Z |
| license_str | Not specified — see source repository |
| provenance_str_mv | Harvested via OAI-PMH from UCTD — University of Cape Town Open Access Repository |
| publishDate | 2025 |
| publishDateRange | 2025 |
| publishDateSort | 2025 |
| publisher | Department of Pathology |
| publisherStr | Department of Pathology |
| record_format | dspace |
| source_str | UCTD — University of Cape Town Open Access Repository |
| spelling | oai:open.uct.ac.za:11427/41087 Associations of genetic variants in ABCB1, ABCG2, CYP3A4, CYP3A5, and SLCO1B1 with statin-associated muscle symptom (SAMS) in South African populations Lusiki, Zizo Dandara, Collet Sinxadi Phumla Medicine Background: Dyslipidaemia, particularly elevated plasma LDL-cholesterol levels, is a key modifiable risk factor for cardiovascular disease (CVD). Statins recognized as LDL-c lowering drugs, have traditionally been the cornerstone in dyslipidaemia treatment and are reported to reduce CVD mortality by 20-30%. However, over the years, the efficacy of statins has been compromised by the emergence of adverse effects, especially statinassociated muscle symptoms (SAMS). Strong evidence links SAMS susceptibility to pharmacogenetic variability of ABCB1, ABCG2, CYP3A4, CYP3A5, and SLCO1B1, particularly in Asian and European populations. However, limited knowledge exists regarding the impact of pharmacogenetics on statin tolerance among South African patients. This study aimed to examine the relationships between genetic variants in the five pharmacogenes mentioned and SAMS in a cohort of dyslipidaemia patients from South Africa undergoing statin treatment. Methods: Employing a retrospective matched case-control (1:2) study design, we assessed a cohort of 332 dyslipidaemia patients from Groote Schuur Hospital, South Africa. Most patients were of Mixed Ancestry. A lipid expert determined SAMS status through adjudication. Genetic variants in five key genes—ABCB1 (rs1045642), ABCG2 (rs2231142, rs2199939), CYP3A4 (rs2740574), CYP3A5 (rs776746, rs10264272, and rs41303343), and SLCO1B1 (rs4149056, rs2306283, and rs4363657)—were chosen for genotyping, using PCR-RFLP, TaqMan genotyping assays, and validated through Sanger sequencing. Statistical analysis, encompassing Chi-Square, Mann-Whitney U (Wilcoxon rank sum), and logistic regression tests, was conducted using STATA v15 and R, while linkage disequilibrium and haplotype analysis were performed using SHEsis online software. Non-genetic and genetic variables were correlated with SAMS status. Results: The median age of patients was 58 years, with 50% being female. Univariate analysis revealed significant associations of SAMS with BMI (p=0.026), waist circumference (p=0.03), and triglyceride levels (p=0.01). The ABCB1 rs1045642 C/T genotype (56.36%, OR=1.86, 95%CI=1.10-3.14, p=0.02) was more prevalent among patients with SAMS compared to those without. Conversely, ABCG2 rs2231142 A/A (6.31%, OR=0.13, 95%CI=0-0.81, p=0.02) and SLCO1B1 rs4149056 C/C (6.76%, OR=0.14, 95%CI=0-0.84, p= 0.03) genotypes were significantly less prevalent in cases than controls. The ABCG2 rs2231142A variant allele occurred more frequently in controls (p=0.03). Multivariate analysis, incorporating genetic and clinical variables through stepwise logistic regression, identified ABCB1 rs1045642 C/T as the sole significant predictor for SAMS in this cohort. Moreover, the SLCO1B1 rs4149056T>C and SLCO1B1 rs4363657T>C polymorphisms exhibited strong linkage disequilibrium—further analysis identified six inferred haplotypes for SLCO1B1. Haplotype 6 (G-T-T) was significantly more prevalent in cases (38.9%, OR=1.44, 95%CI=1.03-2.03, p=0.03) than in controls. Conversely, haplotype 2 (G-C-C) exhibited a significantly higher occurrence in controls (6.8%, OR=0.23, 95%CI=0.08-0.69, p=0.04) than in cases. Conclusion: This study underscores the role of genetic variations in ABCB1, ABCG2, and SLCO1B1 in predisposing South African Mixed Ancestry patients to SAMS. Specifically, ABCB1 rs1045642 C/T genotype emerged as a significant predictor for SAMS in this cohort, indicating its potential role in statin toxicity. Significant differences were observed in the distribution of variant alleles for most SNPs in our cohort compared to global populations, suggesting that universal guidelines may not be universally applicable. This observation was further supported by disparities in inferred haplotypes, underscoring the necessity for comprehensive pharmacogenetic studies within the South African population. These findings expand our knowledge of SAMS in a population with limited pharmacogenomic data, potentially informing personalized statin therapy. Key Words: dyslipidaemia, SAMS, pharmacogenetics, ABCB1, ABCG2, SLCO1B1, South African 2025-03-04T08:52:29Z 2025-03-04T08:52:29Z 2024 2025-03-04T08:46:04Z Thesis / Dissertation Masters MSc http://hdl.handle.net/11427/41087 Eng application/pdf Department of Pathology Faculty of Health Sciences University of Cape Town |
| spellingShingle | Medicine Lusiki, Zizo Associations of genetic variants in ABCB1, ABCG2, CYP3A4, CYP3A5, and SLCO1B1 with statin-associated muscle symptom (SAMS) in South African populations |
| thesis_degree_str | Master's |
| title | Associations of genetic variants in ABCB1, ABCG2, CYP3A4, CYP3A5, and SLCO1B1 with statin-associated muscle symptom (SAMS) in South African populations |
| title_full | Associations of genetic variants in ABCB1, ABCG2, CYP3A4, CYP3A5, and SLCO1B1 with statin-associated muscle symptom (SAMS) in South African populations |
| title_fullStr | Associations of genetic variants in ABCB1, ABCG2, CYP3A4, CYP3A5, and SLCO1B1 with statin-associated muscle symptom (SAMS) in South African populations |
| title_full_unstemmed | Associations of genetic variants in ABCB1, ABCG2, CYP3A4, CYP3A5, and SLCO1B1 with statin-associated muscle symptom (SAMS) in South African populations |
| title_short | Associations of genetic variants in ABCB1, ABCG2, CYP3A4, CYP3A5, and SLCO1B1 with statin-associated muscle symptom (SAMS) in South African populations |
| title_sort | associations of genetic variants in abcb1 abcg2 cyp3a4 cyp3a5 and slco1b1 with statin associated muscle symptom sams in south african populations |
| topic | Medicine |
| url | http://hdl.handle.net/11427/41087 |
| work_keys_str_mv | AT lusikizizo associationsofgeneticvariantsinabcb1abcg2cyp3a4cyp3a5andslco1b1withstatinassociatedmusclesymptomsamsinsouthafricanpopulations |